Decibel Reports Q1 2026 Financial Results

CALGARY – Decibel Cannabis Company Inc. posted its financial results for the first quarter of 2026, showing notable gains in both domestic and international operations. The producer highlighted continued momentum from its branded products in Canada and a sharp rise in export activity.

The company reported net revenue of $29.8 million for the three months ended March 31, 2026. This figure represents a 41% increase from the same period a year earlier. International sales reached $9.6 million, climbing 330% year-over-year and making up a much larger share of the total. Domestic Canadian recreational sales came in at $20.3 million, up 7%. Gross margin before fair value adjustments held steady at 51%, a slight improvement from 50% in the prior-year quarter. Adjusted EBITDA doubled to $6.9 million. The company recorded a net loss of $2.2 million, compared with a $1.9 million loss in the first quarter of 2025.

Decibel also announced progress on its balance sheet. It closed a new $61 million credit facility with ATB Financial that extends debt maturities and provides additional flexibility. The company further agreed to sell its Creston, British Columbia cultivation property for $2.5 million, a move expected to generate annual savings of about $4 million once completed. For the second quarter, Decibel guided net revenue between $33 million and $35 million. It reaffirmed full-year 2026 targets of $130 million to $135 million in net revenue and $27 million to $31 million in adjusted EBITDA.

The international push is where management has placed its biggest bets. Decibel shipped GMP-extracted product into Germany in Q1 2026, marking its first deliveries into the largest medical Cannabis market in the EU, and now holds supply agreements with more than 16 international customers.

International revenue came in at $9.6 million for the quarter, a 330% increase year over year – a remarkable expansion, though growth was partially held back by delays in German permit timelines that have since improved materially heading into Q2. The EU-facing infrastructure behind these numbers is Decibel’s AgMedica subsidiary, whose EU GMP-certified platform continues to perform well above its original underwriting case, validating a cross-border strategy the company has been building since acquiring the Ontario-based operation.

Decibel’s Q1 results reflect a company executing a deliberate pivot – trimming the fixed cost base, monetizing idle assets, and channeling capacity toward European medical demand. The German market opportunity is real, though regulatory timelines have proven uneven, and converting a growing backlog into recognized revenue remains the near-term test. Domestically, the excise tax overhang and a competitive retail shelf continue to limit margin expansion regardless of brand gains. If the full-year guidance holds, Decibel would deliver its most profitable year on record. The open question, as always in Canadian Cannabis, is execution, and whether the European pipeline accelerates fast enough to offset the structural ceiling on home turf.